The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Open accessAbstract
BACKGROUND: Approximately 50 to 60% of patients with essential thrombocythemia or primary myelofibrosis carry a mutation in the Janus kinase 2 gene (JAK2), and an additional 5 to 10% have activating mutations in the thrombopoietin receptor gene (MPL). So far, no specific molecular marker has been identified in the remaining 30 to 45% of patients. METHODS: We performed whole-exome sequencing to identify somatically acquired mutations in six patients who had primary myelofibrosis without mutations in JAK2 or MPL. Resequencing of CALR, encoding calreticulin, was then performed in cohorts of patients with myeloid neoplasms. RESULTS: Somatic insertions or deletions in exon 9 of CALR were detected in all patients who underwent whole-exome sequencing. Resequencing in 1107 samples from patients with myeloproliferative neoplasms showed that CALR mutations were absent in polycythemia vera. In essential thrombocythemia and primary myelofibrosis, CALR mutations and JAK2 and MPL mutations were mutually exclusive. Among patients with essential thrombocythemia or primary myelofibrosis with nonmutated JAK2 or MPL, CALR mutations were detected in 67% of those with essential thrombocythemia and 88% of those with primary myelofibrosis. A total of 36 types of insertions or deletions were identified that all cause a frameshift to the same alternative reading frame and generate a novel C-terminal peptide in the mutant calreticulin. Overexpression of the most frequent CALR deletion caused cytokine-independent growth in vitro owing to the activation of signal transducer and activator of transcription 5 (STAT5) by means of an unknown mechanism. Patients with mutated CALR had a lower risk of thrombosis and longer overall survival than patients with mutated JAK2. CONCLUSIONS: Most patients with essential thrombocythemia or primary myelofibrosis that was not associated with a JAK2 or MPL alteration carried a somatic mutation in CALR. The clinical course in these patients was more indolent than that in patients with the JAK2 V617F mutation. (Funded by the MPN Research Foundation and Associazione Italiana per la Ricerca sul Cancro.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Calreticulin gene (CALR) mutations frequently occur in Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), primary myelofibrosis (PMF), and polycythemia vera (PV) [188–190].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [189]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Self-citationMutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E. P., Ebert, B. L., Gozo, M. C., Cuker, A. C., Wernig, G., Moore, S. A., Galinsky, I. A., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,445
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
Scott, L. M., Tong, W., Levine, R. L., Scott, M., Beer, P., Stratton, M. R., Futreal, P., Erber, W., McMullin, M., Harrison, C. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065202 · Cited by 1,346
The Analysis of Failure Times in the Presence of Competing Risks
Prentice, R. L., Kalbfleisch, J. D., Peterson, A. V., Flournoy, N., Farewell, V. T., & Breslow, N. E. (1978) · Biometrics · doi:10.2307/2530374 · Cited by 1,266
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139
Passamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E. M., Caramella, M., Maffioli, M., et al. (2009) · Blood · doi:10.1182/blood-2009-09-245837 · Cited by 997
Self-citationMutations and prognosis in primary myelofibrosis
Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A. D., Pereira, A., Finke, C. M., Score, J., Gangat, N., Mannarelli, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.119 · Cited by 793
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,001
Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
Sankar, K. N., Stein, B. L., & Rampal, R. K. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-20315-3_11 · Cited by 23
The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance
Rumi, E., Trotti, C., Vanni, D., Casetti, I. C., Pietra, D., & Sant’Antonio, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238885 · Cited by 23
Self-citationJiang, L., Pallavajjala, A., Huang, J., Haley, L. M., Morsberger, L. A., Stinnett, V., Hardy, M., Park, R., Ament, C., Finch, A., et al. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.01.011 · Cited by 23
Haage, T. R., Charakopoulos, E., Bhuria, V., Baldauf, C. K., Korthals, M., Handschuh, J., Müller, P., Li, J., Harit, K., Nishanth, G., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01562-5 · Cited by 23
Looking for CALR mutations in familial myeloproliferative neoplasms
Maffioli, M., Genoni, A. P., Caramazza, D., Mora, B., Bussini, A., Merli, M., Toni Giorgino, A., Casalone, R., & Passamonti, F. (2014) · Leukemia · doi:10.1038/leu.2014.33 · Cited by 22
Kolibaba, K. S., Sterchele, J. A., Joshi, A. D., Forsyth, M., Alwon, E., Beygi, H., & Kennealey, G. T. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620713478629 · Cited by 22
Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies
Klausen, U., Holmberg, S., Holmström, M. O., Jørgensen, N. G. D., Grauslund, J. H., Svane, I. M., & Andersen, M. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02264 · Cited by 22
The role of calreticulin mutations in myeloproliferative neoplasms
Araki, M., & Komatsu, N. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02800-0 · Cited by 22
Bernardi, S., & Farina, M. (2021) · Biology · doi:10.3390/biology10020105 · Cited by 23
Masselli, E., Carubbi, C., Gobbi, G., Mirandola, P., Galli, D., Martini, S., Bonomini, S., Crugnola, M., Craviotto, L., Aversa, F., et al. (2015) · Leukemia · doi:10.1038/leu.2015.150 · Cited by 23
Acute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative Neoplasms
Czader, M., & Orazi, A. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpzqk40jozzzcc · Cited by 23
Li, B., Gale, R. P., & Xiao, Z. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0093-1 · Cited by 22
Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations
Cahu, X., & Constantinescu, S. N. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0278-x · Cited by 22
Contemporary approach to essential thrombocythemia and polycythemia vera
Aruch, D. B., & Mascarenhas, J. O. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000216 · Cited by 22
α-Integrin expression and function modulates presentation of cell surface calreticulin
Liu, C.-C., Leclair, P., Monajemi, M., Sly, L. M., Reid, G. S. D., & Lim, C. J. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.176 · Cited by 22
Talati, C., & Padron, E. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0350-1 · Cited by 22
Buduo, C. A. D., Balduini, A., & Moccia, F. D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122055 · Cited by 22
INDELseek: detection of complex insertions and deletions from next-generation sequencing data
Au, C. H., Leung, A. Y. H., Kwong, A., Chan, T. L., & Ma, E. S. K. (2017) · BMC Genomics · doi:10.1186/s12864-016-3449-9 · Cited by 23
Chuzi, S. E., & Stein, B. L. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1312371 · Cited by 22
Al-Dewik, N. I. E., Tawfeg, B.-O., Zayed, H., Trujillano, D., Kishore, S., Rolfs, A., & Yassin, M. A. (2018) · Gene · doi:10.1016/j.gene.2018.12.009 · Cited by 22
Jain, T., Kunze, K. L., Mountjoy, L. J., Partain, D. K., Kosiorek, H., Khera, N., Hogan, W. J., Roy, V., Slack, J. L., Noël, P., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0302-9 · Cited by 22
Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms
El-Khoury, M., Cabagnols, X., Mosca, M., Vertenoeil, G., Marzac, C., Favale, F., Bluteau, O., Lorre, F., Tisserand, A., Moraes, G. R., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1368-3 · Cited by 25
Magor, G. W., Tallack, M. R., Klose, N., Taylor, D. L., Korbie, D. J., Mollee, P. N., Trau, M., & Perkins, A. C. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.05.006 · Cited by 22
Tefferi, A., & Pardanani, A. D. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01029-3 · Cited by 22
CALRandASXL1mutation analysis in 190 patients with essential thrombocythemia
Shen, H., Chao, H., Ding, Z., Feng, Y., Cen, J., Pan, J., He, J. L., Zhou, M., Chen, Z., & Chen, S. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.939963 · Cited by 21
Iurlo, A., Cattaneo, D., Gianelli, U., Fermo, E., Augello, C., & Cortelezzi, A. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2249-z · Cited by 21
Novel myelofibrosis treatment strategies: potential partners for combination therapies
Stein, B. L., Swords, R. T., Hochhaus, A., & Giles, F. J. (2014) · Leukemia · doi:10.1038/leu.2014.176 · Cited by 21
Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis
Gupta, V. K., Gotlib, J. R., Radich, J. P., Kröger, N. M., Rondelli, D., Verstovšek, S., & Deeg, H. J. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.03.017 · Cited by 22
The evolution and clinical relevance of prognostic classification systems in myelofibrosis
Bose, P., & Verstovšek, S. (2015) · Cancer · doi:10.1002/cncr.29842 · Cited by 21
Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice
Lee, J., Godfrey, A. L., & Nangalia, J. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100708 · Cited by 21
Achyutuni, S., Nivarthi, H., Majoros, A., Hug, E., Schueller, C. M., Jia, R., Varga, C., Schuster, M. K., Senekowitsch, M., Tsiantoulas, D., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26171 · Cited by 21
Self-citationCDK6 Is a Therapeutic Target in Myelofibrosis
Dutta, A., Nath, D., Yang, Y., Le, B. T., & Mohi, G. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0590 · Cited by 24
Chen, M., Zhang, C., Hu, Z., Li, Z., Li, M., Wu, L., Zhou, M., & Liang, D. (2021) · Biosensors · doi:10.3390/bios11080247 · Cited by 21
Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells
Baumeister, J., Maié, T., Chatain, N., Gan, L., Weinbergerová, B., Toledo, M. A. S., Eschweiler, J., Maurer, A., Mayer, J., Kubešová, B., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04615-8 · Cited by 21
Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events
Schmidt, S. U., Daniliants, D., Hiller, E., Gunsilius, E., Wolf, D. G. F., & Feistritzer, C. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004061 · Cited by 21
A Chaperone-Like Role for EBI3 in Collaboration With Calnexin Under Inflammatory Conditions
Watanabe, A., Mizoguchi, I., Hasegawa, H., Katahira, Y., Inoué, S., Sakamoto, E., Furusaka, Y., Sekine, A., Miyakawa, S., Murakami, F., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.757669 · Cited by 21
The regulation roles of Ca2+ in erythropoiesis: What have we learned?
Zhang, Y., Xu, Y., Zhang, S., Lu, Z., Li, Y., & Zhao, B. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.12.192 · Cited by 23
Feenstra, J. D. M., Jäger, R., Schischlik, F., Ivanov, D., Eisenwort, G., Rumi, E., Schuster, M. K., Gisslinger, B., Machherndl‐Spandl, S., Bettelheim, P., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26461 · Cited by 23
Self-citationMutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN
Paşca, S., Chifotides, H. T., Verstovšek, S., & Bose, P. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2021.02.008 · Cited by 22
Causes of Thrombocytosis: A Single-center Retrospective Study of 1,202 Patients
Edahiro, Y., Kurokawa, Y., Morishita, S., Yamamoto, T. S., Araki, M., & Komatsu, N. (2022) · Internal Medicine · doi:10.2169/internalmedicine.9282-21 · Cited by 21
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
Guglielmelli, P., Maccari, C., Sordi, B., Balliu, M., Atanasio, A., Mannarelli, C., Capecchi, G., Sestini, I., Coltro, G., Loscocco, G. G., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00786-x · Cited by 21
Foßelteder, J., Pabst, G., Sconocchia, T., Schlacher, A., Auinger, L., Kashofer, K., Beham‐Schmid, C., Trajanoski, S., Waskow, C., Schöll, W., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01848-6 · Cited by 21
Hindilerden, İ. Y., Aday, A. D., Akadam-Teker, B., Yılmaz, C., Nalçacı, M., Yavuz, A. S., & Sargın, D. (2015) · Journal of Blood Medicine · doi:10.2147/jbm.s78826 · Cited by 21
Barosi, G., Rosti, V., & Gale, R. P. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s31916 · Cited by 21
Li, N., Yao, Q.-M., Gale, R. P., Li, J., Li, L.-D., Zhao, X.-S., Jiang, H., Jiang, Q., Jiang, B., Shi, H., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.02.006 · Cited by 21
Guglielmelli, P., Bisognin, A., Saccoman, C., Mannarelli, C., Coppe, A., Vannucchi, A. M., & Bortoluzzi, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140445 · Cited by 21
Ahmed, R. Z., Rashid, M., Ahmed, N., Nadeem, M. A., & Shamsi, T. S. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.3.923 · Cited by 21
Development of paroxysmal nocturnal hemoglobinuria in CALR-positive myeloproliferative neoplasm
Moliterno, A. R., Fraiman, Y. S., Cuka, N. S., Batista, D., & Vuica‐Ross, M. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s103473 · Cited by 21
Anelli, L., Zagaria, A., Coccaro, N., Tota, G., Minervini, A., Casieri, P., Impera, L., Minervini, C. F., Brunetti, C., Ricco, A., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2739-2 · Cited by 21
Biology of Myeloproliferative Malignancies
Melikyan, A. L., & Subortseva, I. N. (2016) · Clinical oncohematology · doi:10.21320/2500-2139-2016-9-3-314-325 · Cited by 22
Agarwal, R., Blombery, P. A., McBean, M., Jones, K. L., FELLOWES, A. P., Doig, K., Forsyth, C. J., & Westerman, D. (2017) · Annals of Hematology · doi:10.1007/s00277-017-2937-6 · Cited by 21
Takei, H., Edahiro, Y., Mano, S., Masubuchi, N., Mizukami, Y., Imai, M., Morishita, S., Misawa, K., Ochiai, T., Tsuneda, S., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15266 · Cited by 21
Ruxolitinib for the Treatment of Essential Thrombocythemia
Gunawan, A. S., Harrington, P., Garcia-Curto, N., McLornan, D. P., Radia, D. H., & Harrison, C. N. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000056 · Cited by 24
Cancer immune therapy for myeloid malignancies: present and future
Holmström, M. O., & Hasselbalch, H. C. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0693-x · Cited by 23
Mikič, T. B., Pajič, T., & Sever, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-56236-x · Cited by 21
Splicing Anomalies in Myeloproliferative Neoplasms: Paving the Way for New Therapeutic Venues
Hautin, M., Mornet, C., Chauveau, A., Bernard, D. G., Corcos, L., & Lippert, É. (2020) · Cancers · doi:10.3390/cancers12082216 · Cited by 23
Coltro, G., Loscocco, G. G., & Vannucchi, A. M. (2021) · International review of cytology · doi:10.1016/bs.ircmb.2021.09.001 · Cited by 25
Jutzi, J. S., Marneth, A. E., Ciboddo, M., Guerra-Moreno, Á., Jiménez‐Santos, M. J., Kosmidou, A., Dressman, J. W., Liang, H., Hamel, R., Lozano, P., et al. (2022) · Blood · doi:10.1182/blood.2022015629 · Cited by 22
Self-citationOsorio, M. J. M., Ferrari, L. C., Goette, N. P., Gutiérrez, M. I., Glembotsky, A. C., Maldonado, A. C., Lev, P. R., Alvarez, C., Korin, L., Marta, R. F., et al. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12614 · Cited by 21
Rontauroli, S., Norfo, R., Pennucci, V., Zini, R., Ruberti, S., Bianchi, E., Salati, S., Prudente, Z., Rossi, C., Rosti, V., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15226 · Cited by 21
Biology of Erythropoiesis, Erythroid Differentiation, and Maturation
Papayannopoulou, T., & Migliaccio, A. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00026-3 · Cited by 21
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives
Loscocco, G. G., & Guglielmelli, P. (2025) · American Journal of Hematology · doi:10.1002/ajh.27658 · Cited by 23
Actuación ante la trombosis portal no cirrótica no tumoral
Llop, E., & Seijó, S. (2015) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2015.09.007 · Cited by 20
Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms
Falanga, A., Marchetti, M., & Schieppati, F. (2021) · Hämostaseologie · doi:10.1055/a-1334-3259 · Cited by 20
The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms
Mikič, T. B., Pajič, T., Zver, S., & Sever, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073371 · Cited by 20
Clinical impact of glycans in platelet and megakaryocyte biology
Falet, H., Rivadeneyra, L., & Hoffmeister, K. M. (2022) · Blood · doi:10.1182/blood.2020009303 · Cited by 20
Single-cell methods in myeloproliferative neoplasms: old questions, new technologies
O’Sullivan, J., Mead, A. J., & Psaila, B. (2022) · Blood · doi:10.1182/blood.2021014668 · Cited by 24
Wojtaszewska, M. L., Iwoła, M., & Lewandowski, K. C. (2014) · Acta Haematologica · doi:10.1159/000366263 · Cited by 20
Gianelli, U., Iurlo, A., Cattaneo, D., Bossi, A., Cortinovis, I., Augello, C., Moro, A., Savi, F., Castelli, R., Brambilla, C., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.03.009 · Cited by 20
Prick, J. C. M., de Haan, G., Green, A. R., & Kent, D. G. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.07.268 · Cited by 21
Kamal, T., Green, T. N., Morel‐Kopp, M., Wård, C., McGregor, A. L., McGlashan, S. R., Bohlander, S. K., Browett, P., Teague, L. R., During, M. J., et al. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.05.004 · Cited by 21
Duployez, N., Lejeune, S., Renneville, A., & Preudhomme, C. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1257936 · Cited by 21
Splicing factor mutations in MDS RARS and MDS/MPN-RS-T
Yoshimi, A., & Abdel-Wahab, O. I. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2242-0 · Cited by 20
Nielsen, H. M., Andersen, C. L., Westman, M. K., Kristensen, L. S., Asmar, F., Kruse, T. A., Thomassen, M., Larsen, T. S., Skov, V., Hansen, L. L., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07057-3 · Cited by 20
Schulze, S., Stengel, R., Jaekel, N., Wang, S., Franke, G., Roskos, M., Schneider, M., Niederwieser, D. W., & Al‐Ali, H. K. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22781 · Cited by 20
Pathogenic Effects of Impaired Retrieval between the Endoplasmic Reticulum and Golgi Complex
Kokubun, H., Jin, H., & Aoe, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225614 · Cited by 20
JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis
Maddali, M., Kulkarni, U. P., Ravindra, N., Jajodia, E., Arunachalam, A. K., Suresh, H., Venkatraman, A., George, B., Mathews, V., & Balasubramanian, P. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04004-7 · Cited by 20
Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin
Edahiro, Y., Araki, M., & Komatsu, N. (2020) · Cancer Science · doi:10.1111/cas.14503 · Cited by 20
Myeloid somatic mutation panel testing in myeloproliferative neoplasms
Ross, D. M., Thomson, C., Hamad, N., Lane, S., Manos, K., Grigg, A., Guo, B. B., Erber, W. N., Scott, A. P., Viiala, N., et al. (2021) · Pathology · doi:10.1016/j.pathol.2021.01.003 · Cited by 20
Marković, D. C., Maslovarić, I. S., Djikić, D., & Čokić, V. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031490 · Cited by 20
Mughal, F. P., Bergmann, A. C., Huynh, H. U. B., Jørgensen, S. H., Mansha, I., Kesmez, M., Schürch, P. M., Theocharides, A. P. A., Hansen, P. B., Friis, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126803 · Cited by 20
Nunes, D. P. T., de Lima, L. T., Chauffaille, M. D. L., Mitne‐Neto, M., dos Santos, M. T., Cliquet, M. G., & Guerra‐Shinohara, E. M. (2015) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2015.07.005 · Cited by 20
Okabe, M., Yamaguchi, H., Usuki, K., Kobayashi, Y., Kawata, E., Kuroda, J., Kimura, S. H., Tajika, K., Gomi, S., Arima, N., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.11.002 · Cited by 20
Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms
Khan, I., Shergill, A. P., Saraf, S. L., Chen, Y., Patel, P. R., Quigley, J. G., Peace, D. J., Gordeuk, V. R., Hoffman, R., & Rondelli, D. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.02.036 · Cited by 20
Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology
Hussaini, M. (2015) · Cancer Control · doi:10.1177/107327481502200206 · Cited by 20
Tsang, H. C., Bussel, J. B., Mathew, S., Liu, Y., Imahiyerobo, A., Orazi, A., & Geyer, J. T. (2017) · Modern Pathology · doi:10.1038/modpathol.2016.218 · Cited by 20
Malcovati, L., Rumi, E., & Cazzola, M. (2014) · Haematologica · doi:10.3324/haematol.2014.113944 · Cited by 20
Self-citationIt is time to change thrombosis risk assessment for PV and ET?
Passamonti, F., Caramazza, D., Mora, B., Casalone, R., & Maffioli, M. (2014) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.07.005 · Cited by 19
CALR versus JAK 2 mutated essential thrombocythaemia – a report on 141 patients
Trifa, A. P., Popp, R. A., Cucuianu, A., Bănescu, C. V., Tevet, M., Martin, B., Murat, M., Vesa, Ș. C., Dima, D. M., Cândea, M., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13076 · Cited by 19
Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review
Farhadfar, N., Cerquozzi, S., Patnaik, M. M., & Tefferi, A. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.013268 · Cited by 19
Haque, L., & Lim, J. K. (2020) · Clinics in Liver Disease · doi:10.1016/j.cld.2020.04.012 · Cited by 19
Holmström, M. O., Andersen, M., Traynor, S., Ahmad, S. M., Lisle, T. L., Grauslund, J. H., Skov, V., Kjær, L., Ottesen, J. T., Gjerstorff, M. F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1240678 · Cited by 19
Goto, K., Kiniwa, Y., Kukita, Y., Ohe, S., Hiraki, T., Hishima, T., Takai, T., & Honma, K. (2024) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002195 · Cited by 19
Bhuria, V., Franz, T. J., Baldauf, C. K., Böttcher, M., Chatain, N., Koschmieder, S., Brümmendorf, T. H., Mougiakakos, D., Schraven, B. L., Kahlfuß, S., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01530-z · Cited by 19
Sano, H., Ohki, K., Park, H., Shiba, N., Hara, Y., Sotomatsu, M., Tomizawa, D., Taga, T., Kiyokawa, N., Tawa, A., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13439 · Cited by 19
CALR mutations are rare in childhood essential thrombocythemia
Langabeer, S. E., Haslam, K., & McMahon, C. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.24984 · Cited by 19
Todisco, G., Manshouri, T., Verstovšek, S., Masárová, L., Pierce, S. A., Keating, M. J., & Estrov, Z. E. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1092527 · Cited by 19
Saki, N., Seghatoleslami, M., Ketabchi, N., Ordo, A., Asl, J. M., & Golchin, N. (2015) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2016.002 · Cited by 19
Thrombotic risk correlates with mutational status in true essential thrombocythemia
Bertozzi, I., Peroni, E., Coltro, G., Bogoni, G., Cosi, E., Santarossa, C., Fabris, F., & Randi, M. L. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12647 · Cited by 19
Singdong, R., Siriboonpiputtana, T., Chareonsirisuthigul, T., Kongruang, A., Limsuwanachot, N., Sirirat, T., Chuncharunee, S., & Rerkamnuaychoke, B. (2016) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2016.17.10.4647 · Cited by 19
Metadata
- Authors
- Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., Them, N. C. C., Berg, T., Gisslinger, B., Pietra, D., Chen, D., Vladimer, G. I., Bagienski, K., Milanesi, C., Casetti, I. C., Sant'Antonio, E., Ferretti, V., Elena, C., Schischlik, F., Cleary, C., Six, M., Schalling, M., Schönegger, A., Bock, C., Malcovati, L., Pascutto, C., Superti-Furga, G., Cazzola, M., & Kralovics, R.
- Affiliations
- Austrian Academy of Sciences (AT)
- Medical University of Vienna (AT)
- Policlinico San Matteo Fondazione (IT)
- University of Pavia (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-12-19
- Volume
- 369
- Issue
- 25
- Pages
- 2379-2390
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2157694607
- Cited by
- 2,003
- References
- 32
- Citations by year
- 2026: 80 · 2025: 63 · 2024: 81 · 2023: 117 · 2022: 122 · 2021: 173 · 2020: 144 · 2019: 146 · 2018: 153 · 2017: 200 · 2016: 247 · 2015: 243 · 2014: 222 · 2013: 7
- FWCI
- 118.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- calreticulin, CALR mutation, myeloproliferative neoplasms, essential thrombocythemia, primary myelofibrosis, JAK2 V617F mutation, MPL mutation, somatic mutations, exon 9 deletion, frameshift mutation, STAT5 activation, thrombosis risk, overall survival
- MeSH terms
- Bone Marrow Diseases, Exons, Humans, Leukemia, Myeloid, Mutation, Thrombocythemia, Essential, Thrombosis, Proportional Hazards Models, Polymerase Chain Reaction, Sequence Analysis, DNA, Calreticulin, Janus Kinase 2, Receptors, Thrombopoietin, Primary Myelofibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
